MedTrace Logo

Effectiveness and Safety of Yiqitongluo Granule for Stroke

NCT02604654 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2197

Last updated 2021-08-25

No results posted yet for this study

Summary

The purpose of the prospective study is to evaluate the effectiveness and safety of Yiqitongluo granule in the treatment of stroke with qi-deficiency and blood-stasis in more than sixy hospitals all over China.

Conditions

Interventions

DRUG

Yiqitongluo granule

administered after dissolved

Sponsors & Collaborators

  • Shineway Pharmaceutical Co.,Ltd

    collaborator INDUSTRY

  • Yi Yang

    lead OTHER

Principal Investigators

  • Yi Yang · The First Hospital of Jilin University

  • Zhenni Guo · The First Hospital of Jilin University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-29
Primary Completion
2017-11-05
Completion
2017-12-06

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02604654 on ClinicalTrials.gov